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Despite extensive investigation, the precise contribution of the ultraviolet radiation (UVR) component of sunlight to melanoma
etiologyremainsunclear.UVRinduceskeratinocytestosecreteproinﬂammatoryandimmunomodulatorymediatorsthatpromote
inﬂammation and skin tumor development; expression of the slug transcription factor in keratinocytes is required for maximal
production of these mediators. In the present studies we examined the possibility that UVR-exposed melanocytes also produce
proinﬂammatory mediators and that Slug is important in this process. Microarray studies revealed that both UVR exposure and
Slug overexpression altered transcription of a variety of proinﬂammatory mediators by normal human melanocytes; some of these
mediators are also known to stimulate melanocyte growth and migration. There was little overlap in the spectra of cytokines
producedbythetwostimuli.HoweverIL-20wassimilarlyinducedbybothstimuliandtheNFκBpathwayappearedtobeimportant
in both circumstances. Further exploration of UVR-induced and Slug-dependent pathways of cytokine induction in melanocytes
may reveal novel targets for melanoma therapy.
1.Introduction
Althoughtheincidenceofmelanomaisincreasingfasterthan
that of any other neoplasm and the tumor has been studied
intensively, the cause of melanoma remains incompletely
understood. It is clear from epidemiologic and clinical ob-
servations that the ultraviolet (UVR) component of sunlight
is an important etiologic factor; however, the precise mecha-
nisms by which UVR drives melanomagenesis are unknown
[1–4]. Mutations in oncogenes and tumor suppressor genes
have been identiﬁed in melanomas, but most of these are not
the UVR signature mutations found in nonmelanoma skin
cancers [5]. This suggests an indirect role for UVR in mela-
nomagenesis, likely as a tumor promoter [6].
An important mechanism for tumor promotion is the
creationofatumormicroenvironmentthatfosterstumorcell
proliferation and migration while suppressing an eﬀective
immune response to the tumor cells. It has been shown that
manytumorcelltypesandtheirprecursorssecreteawideva-
riety of proinﬂammatory and immunomodulatory sub-
stances [7, 8]. For instance, UVR exposure of keratinocytes
promotes the production of cytokines, chemokines, and
prostaglandins that strongly promote nonmelanoma skin
cancer [9]. Our studies in mice have shown that the Slug
(Snai2) transcription factor plays a critical role in UVR-
induced cutaneous inﬂammation. Slug knockout mice are
highly sunburn resistant, apparently because Slug knockout
keratinocytesareunabletosecreteappropriateproinﬂamma-
tory mediators [10].
Based on our ﬁndings in keratinocytes, we examined the
possibility that UVR also induces expression of proinﬂam-
matory and immunomodulatory mediators by melanocytes.2 Journal of Skin Cancer
We also investigated a possible role for Slug in modulating
UVR induction of these mediators.
2.MaterialsandMethods
2.1. Cell Culture. Normal human melanocytes of neonatal
origin were obtained from the American Type Tissue Col-
lection (ATCC) and maintained in Dermal Basal Medium
supplemented with Melanocyte Growth Kit (ATCC).
2.2. UVR Exposure. Melanocytes were grown to conﬂuence
then exposed to 300J/m2 UVR and harvested 24 hours later.
UVR was obtained from a bank of Philips TL20 W/12 RS
UVB lamps (American Ultraviolet Company). These lights
emit wavelengths between 280 and 400nm, with a peak at
313nm. The lamps emit approximately 60% UVB wave-
lengths and 40% UVA wavelengths, with less than 3% of the
radiation in the UVC range [11].
2.3. Adenoviral Transduction. M e l a n o c y t e sw e r eg r o w nt o
75% conﬂuence then incubated with adenoviral Slug
(AdSlug) or a control adenovirus (Ad-CMV-Null, Vector
Biolabs) [12]. For transduction, 10μLo fa d e n o v i r a ls t o c k
(viral titer 108 ifu/mL) mixed with one mL of medium was
added to each well of a six-well plate. Cells were incubated
with the adenovirus for 24 hours before the medium was
changed. Cells were harvested 24 hours later, and mRNA was
isolated utilizing the RNeasy kit (Qiagen).
2.4. RT-QPCR. For mRNA analysis cDNA was generated
utilizingtheAppliedBiosystemsHighCapacitycDNARTkit.
Following reverse transcription, RT-QPCR was performed
utilizing applied biosystems assays on demand for Snai2
and 18S together with TaqMan Universal Master Mix.
Ampliﬁcations were carried out on an applied biosystem
7900HT real-time PCR analyzer, utilizing the standard curve
method for quantiﬁcation [13].
2.5. Western Blotting. Whole cell lysates in RIPA buﬀer plus
HALT protease inhibitor cocktail (Thermo Scientiﬁc) were
cleared by centrifuging at 10,000rpm for 10 minutes at 4◦C.
A total of 40μg of protein was loaded on a 4–20% tris-HCL
gel. Following SDS-PAGE, protein was transferred to PVDF
membrane and probed with antibodies against Slug (Cell
Signaling Technology) or GAPDH (Abcam). The secondary
antibody utilized was anti-rabbit IgG HRP (GE Healthcare).
Primary antibodies were used at 1:1000 dilutions, while the
secondary antibody concentration was 1:5000. Blots were
incubated overnight at 4◦C with primary antibody and
two hours at room temperature with secondary antibodies.
Prior to exposure to ﬁlm, membranes were incubated in
Super Signal West ECL (Thermo Fisher Scientiﬁc). For
quantiﬁcation, densitometry was performed.
2.6. Cytokine Arrays. For cytokine proﬁling, the PAHS-
3803 Human Inﬂammatory Response and Autoimmunity
Cytokine Array (SA Biosciences) was employed. This array
quantiﬁes the expression of 370 key genes involved in
immuneresponseandinﬂammation,includinggenesencod-
ing inﬂammatory cytokines, chemokines, and their receptors
as well as genes involved in cytokine synthesis and metab-
olism and in cytokine-cytokine receptor interactions. RNA
was analyzed to check RNA quality using the Agilent RNA
6000 Nano kit. Only RNA with a RIN value less than 7.5
was employed. For each sample, 1000ng of RNA was used to
synthesize the ﬁrst strand of cDNA using the high-capacity
cDNA RT Kit from Applied Biosystems (ABI), following
standard ABI Protocol. The amount of cDNA added to each
of the 96-well plates was standardized. The cDNA was mixed
with iTAQ SYBR Green Supermix (Bio-Rad), and each plate
was run using the ABI Prism 7900 HT instrument using
the following protocol: 10 minutes at 95◦Cf o r1 0m i n u t e s ;
40 cycles of 0.15 seconds at 95◦C and 60 seconds at 60◦C;
15 seconds at 95◦C; 15 seconds at 95◦C and 15 seconds at
95◦C. Analysis of each plate was performed using the SDS
2.3 program from ABI using the same threshold and baseline
for all biological samples. Two independent sets of samples
were analyzed.
2.7. Ingenuity Analysis. Genes with expression levels altered
more than two-fold in both replicate arrays were identiﬁed.
IngenuityPathwayAnalysissoftware(IngenuitySystems)was
used to construct networks that functionally relate genes
with markedly altered expression due to UVR exposure or
Slugoverexpression.Thesenetworksarebasedonalgorithms
that reﬂect the connectivity among diﬀerent genes. A score is
generated that indicates the relevance of any given network
to the input genes (http://www.ingenuity.com/).
3. Results
3.1. UVR Induction of Slug. As shown in Figure 1,n o r m a l
human melanocytes exposed to 300J/m2 UVR showed a
markedinductionofSlugmRNAexpressionat24hoursafter
exposure. However, Slug protein induction was much less
robust, averaging a little less than two-fold at 24 hours. Thus,
as in keratinocytes, Slug expression is UVR inducible [14].
3.2. UVRandSlugInductionof ProinﬂammatoryandImmun-
omodulatory Mediators. Two independent comparisons of
inﬂammatory mediator expression in UVR-exposed versus
unexposed and in Slug overexpressing versus control normal
human melanocytes revealed a number of genes with expres-
sion consistently altered two-fold or more.
Nine genes showed increased expression and six genes
showed decreased expression in UVR-exposed versus unex-
posed melanocytes (Table 1). Genes with the most markedly
increased expression included CXCL2, CXCL3, and IL-8. All
of these genes, as well as the more moderately increased
CXCL1,havebeenshowntobeimportantbothinneutrophil
chemotaxis and in melanoma growth [15, 16]. Increased
expression of PTGS2 (cyclo-oxygenase-2 (COX-2)) is remi-
niscent of the situation in nonmelanoma skin cancer. UVR
induces PTGS2 in keratinocytes, and the gene is overex-
pressed in premalignant and malignant nonmelanoma skin
lesions [17]. Downregulation of NR3C1 (glucocorticoidJournal of Skin Cancer 3
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Figure 1: UVR induction of Slug 24 hours following a dose of
300J/m2 UVR. (a) Slug mRNA levels were determined by RT-
QPCRintwo independent assays, each performed intriplicate. Bars
represent the standard error of all six values. (b) Slug protein levels
were determined by Western blotting followed by densitometry in
three independent assays. Bars represent the standard deviation.
receptor) is of interest, as melanoma cells have recently
been shown to express this receptor and dexamethasone
has an antiproliferative eﬀect on these cells [18]. Other
ﬁndings were less easily understood. PTAFR (platelet-
activating factor receptor) expression was decreased after
UVR, although activation of this receptor on melanoma
cells has been demonstrated to enhance their proliferation,
invasiveness, and metastatic capabilities [19]. Decreased
expression of the NFκB transcription factor and the NFκB
activator RIPK2 was unexpected, as UVR activates the
NFκB pathway in many melanoma cells, and these cells
constitutively express both NFκB and an alternative activator
NIK [20]. The role of CCL2 production by melanoma cells
remains somewhat controversial, as low CCL2 levels appear
to attract tumor-associated macrophages, which promote
tumor development, while high levels of CCL2 production
attract macrophages that cause tumor regression [21]. The
relationship of other genes with altered expression to mela-
nomagenesis has not been explored.
AdSlug-transfected melanocytes show markedly en-
hanced Slug expression [22]. Compared to control melano-
cytes, Slug-overexpressing melanocytes had more than two-
fold increased expression of 13 genes and more than two-
fold decreased expression of two genes. The three genes with
the most markedly altered expression were CCL18, CXCL10,
and IL-4, molecules that are chemotactic for or activate lym-
phocytes [23, 24]. At the same time, IL-4 has been shown to
suppressthegrowthofmelanomacelllinesandenhancetheir
immunogenicity [25], thus enhanced IL-4 expression would
not be expected to enhance melanomagenesis. Nor would
expression of IFNA4, which has been used in melanoma
therapy [26]. Many growth factors stimulate melanocytes
proliferation, including FGF2 [27, 28], thus it seems likely
that FGF10 may also contribute to melanocyte proliferation.
The endothelial protein C receptor (PROCR) is expressed by
a variety of tumor cell types, and protein C appears to stimu-
late tumor cell proliferation, migration, and metastasis [29,
30]; thus, increased expression of PROCR in melanocytes
may stimulate them to proliferate and migrate. Interestingly,
expression of TACR1 (tachykinin receptor) is downregulat-
ed in Slug-overexpressing melanocytes; TACR1 antagonists
drivemelanomacellapoptosis,thusSlugoverexpressionmay
protect melanocytes from apoptosis [31]. In B cells, BLNK
(B-cell linker protein) is important for activation of the
NFκBp a t h w a y[ 32]; however, its expression has not been
reported in other cell types. Little is known about the
role of IL1R2 (IL-1 decoy receptor), IL5RA (IL-5 receptor
component),MGLL(monoglyceridelipase),orSERPINF2in
melanomagenesis.
The only gene with expression similarly increased by
both UVR and Slug overexpression was IL-20, a member of
the IL-10 family of cytokines. IL-20 plays a poorly under-
stood role in cutaneous inﬂammation. It is highly expressed
by keratinocytes in inﬂammatory conditions of the skin-
like psoriasis and atopic dermatitis; however, the role of
the cytokine in keratinocyte biology and immune regulation
remains controversial [33, 34]. Expression of the related IL-
22 cytokine was also increased in Slug-overexpressing cells.
Like IL-20, this gene is clearly important in the interaction
between keratinocytes and immune cells, and its expression
is enhanced in inﬂammatory skin conditions [35].
3.3. Comparison of UVR and Slug-Related Inﬂammatory
Networks. We investigated interactions among the genes
with altered expression in UVR-exposed and in Slug-
overexpressing melanocytes using Ingenuity Pathway Anal-
ysis (Figures 2 and 3). For each condition, a single network
was determined to be highly signiﬁcantly related to the gene
set with altered expression. In both cases, the main functions
of input genes were related to cellular movement, immune
cell traﬃcking, and hematological system development. The4 Journal of Skin Cancer
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Figure 2: Ingenuity Pathway Analysis of altered expression of proinﬂammatory genes in normal human melanocytes. Cells were harvested
24hoursfollowingadoseof300J/m2 UVR.mRNAexpressionlevels weredeterminedusingthePAHS-3803Human InﬂammatoryResponse
andAutoimmunityCytokineArray(SABiosciences),andgeneswithexpressionalteredmorethantwo-foldinduplicateassayswereincluded
in the Ingenuity Pathway Analysis.
P value, which indicates the probability of an association
between genes in the dataset and a given canonical pathway,
was ≤10−30 for both gene sets. However, because the analysis
was based on a limited number of genes preselected for their
involvement in inﬂammation and autoimmunity, this degree
of association is perhaps not remarkable. The canonical
networks identiﬁed accounted for 11/16 genes in the UVR
dataset and 13/16 in the Slug dataset. Many of the gene
i n t e r a c t i o n si nb o t hd a t a s e t sw e r ec e n t e r e da r o u n dN F κB.
The NFκB pathway is constitutively activated in malignant
melanoma and is believed to be responsible for persistent
expression of chemokines by melanoma cells [20]. For Slug,
there was an additional focus centered on ERK and p38
M A P K ;t h i si sn o ts u r p r i s i n g ,a sb o t hS l u gi n d u c t i o na n d
NFκB activation may occur via MAPK pathways [20, 36].
4. Discussion
UVR makes important contributions to skin carcinogenesis.
UVR serves as a complete carcinogen for nonmelanoma skin
cancer: it both induces critical mutations in keratinocytes
and promotes tumor expansion [37]. One of the ways that
UVR promotes the growth of nonmelanoma skin cancers
is by stimulating keratinocytes to release proinﬂammatory
mediators, thus creating a local milieu that promotes tumor
growth [17, 37]. Indeed, anti-inﬂammatory compounds
like COX-2 inhibitors are highly eﬀective in reducing the
progression of UVR-induced nonmelanoma skin cancers in
experimental animals [17]. In melanoma, the role of UVR
is less clear, as the driving mutations in melanoma do not
appear to be due to the direct mutagenic activity of UVR;
instead, UVR appears to promote melanoma development
by creating a proinﬂammatory and immunosuppressive en-
vironment [4]. To date, studies of UVR-induced cutaneous
inﬂammation have focused on the role of proinﬂammatory
mediators released by keratinocytes; however, our present
studies demonstrate that UVR-exposed melanocytes are also
able to produce many of the same mediators. Other ex-
ogenous stimuli have also been reported to induce the
productionofcytokinesandchemokinesbymelanocytesandJournal of Skin Cancer 5
Figure 3: Ingenuity Pathway Analysis of altered expression of proinﬂammatory genes in normal human melanocytes transduced with Ad-
Slug. Expression levels were determined using the PAHS-3803 Human Inﬂammatory Response and Autoimmunity Cytokine Array (SA
Biosciences), and genes with expression altered more than two-fold in duplicate assays were included in the Ingenuity Pathway Analysis.
melanoma cells. Lipopolysaccharides can stimulate normal
human melanocytes to produce IL-1β,T N F α, IL-6, IL-8,
CCL2, CCl3, and CCL5 [38, 39], and chemotherapy of
melanoma-bearing mice results in enhanced expression of
CCL5 and the CXCR3 ligands CXCL9, CXCL10, and CXCl11
by tumor cells [40].
Our previous studies have shown that the Slug tran-
scription factor is an important mediator of UVR-induced
inﬂammation in the skin. Slug knockout mice are highly
resistant to UVR-induced skin inﬂammation because UVR-
exposed Slug knockout keratinocytes release fewer proin-
ﬂammatorymediatorsthanwildtypekeratinocytes[10].The
role of Slug in the production of inﬂammatory mediators in
melanocytes has not previously been investigated. The
p r e s e n ts t u d i e sd e m o n s t r a t et h a tb o t hS l u gm R N Aa n dp r o -
tein are UVR inducible and that Slug overexpression in
melanocytes stimulates chemokine and cytokine expression.
This is particularly interesting, in that Slug is expressed in
many melanomas and is believed to contribute to melanoma
progression [41]. However, our previous studies have sug-
gested that Slug expression is actually maximal early during
melanoma progression [22]. Taken together, our previous
and present ﬁnding suggest that Slug expression early in
melanomagenesis may play an important role in modulating
the inﬂammatory and immune response to melanocytes
early during melanomagenesis.
The spectrum of proinﬂammatory genes with altered
transcription in UVR-exposed versus Slug-overexpressing
melanocytes showed little overlap. In fact, the only proin-
ﬂammatory gene similarly altered in the two conditions was
IL-20, which plays a poorly deﬁned, although potentially
critical role in cutaneous inﬂammation [42].Despite thelack
of overlap in gene expression proﬁles, Ingenuity Pathway
Analysis revealed that both patterns of expression centered
on NFκB, a transcription factor known to play an extremely
important role in melanoma cell production of chemokines
[20]. The additional centering of the Slug pathway on ERK
and p38 MAPK may be related to the fact that both NFκB
and Slug expression are strongly induced by growth factors
like EGF, which signals through the MAPK pathway [20, 36].
Anotherconsiderationininterpretingtheminimaloverlapin
inﬂammatorymediatorexpressioninducedbySlugandUVR
is that we examined only a single time point in what is clearly
a transient UVR response. More detailed characterization of6 Journal of Skin Cancer
Table 1: Altered expression of proinﬂammatory and immunomodulatory mediators by normal human melanocytes.
Treatment Gene UVR-exposed/unexposeda Treatment Gene Slug-transduced/controla
UVR
CCL2 2.50, 6.63
Slug
BLNK 2.99, 2.38
CXCL1 5.06, 3.80 CCL18 4.77, 3.53
CXCL2 6.86, 6.53 CXCL10 4.26, 6.03
CXCL3 10.61, 13.11 FGF10 2.73, 2.77
IL12A 7.41, 2.21 IFNA4 2.53, 3.13
IL1RAP −2.35, −2.07 IFNWP2 2.53, 2.02
IL20 2.66, 2.79 IL1R2 2.88, 4.21
IL8 5.92, 10.21 IL20 2.81, 2.70
NFκB1 −2.95, −2.61 IL22 2.47, 5.09
NFX1 −2.54, −2.49 IL4 3.54, 3.04
NR3C1 −2.80, −2.45 IL5RA 2.49, 4.40
PTAFR −3.06, −2.01 MGLL −2.95, −4.24
PTGS2 2.93, 2.52 PROCR 2.19, 2.34
RIPK2 −2.46, −2.25 SERPINF2 2.56, 2.51
TNFSF9 6.72, 2.86 TACR1 −2.88, −2.92
aV a l u e sf o rb o t hr e p l i c a t ea s s a y sa r es h o w n .
the kinetics of proinﬂammatory gene expression following
UVR exposure may reveal more overlap between Slug and
UVR-modulated genes.
Tumor-derived proinﬂammatory and immunomodula-
tory molecules, like those stimulated by UVR exposure and
Slug expression, clearly inﬂuence tumor growth by modulat-
ing the inﬂammatory and immunologic milieu of the tumor
aswellasbydirectlystimulatingtumorcellproliferation,mi-
gration, and invasion [43]. This makes these molecules
potentially valuable therapeutic targets in prevention and
treatment of melanoma [8, 15, 16, 21]. For example,
COX-2 inhibitors have been shown to be cytotoxic and
cytostatic for human melanoma cells in vitro and to have
potentially beneﬁcial eﬀects in melanoma therapy [44, 45].
This suggests that further exploration of UVR and Slug-
induced proinﬂammatory and immunomodulatory media-
tors is warranted.
5. Conclusion
Both UVR exposure and Slug overexpression induce al-
terations in the production of proinﬂammatory and im-
munomodulatorymediatorsbynormalhumanmelanocytes.
These melanocyte-derived cytokines and chemokines may
have important eﬀects on the inﬂammatory milieu, prolifer-
ation,andmotilityofmelanocytesandthemelanomacellsto
which they give rise. Further study will be required to deter-
mine the extent to which Slug mediates the eﬀect of UVR
on the induction of inﬂammatory mediators in melanocytes.
Additional studies of cytokine and chemokine induction in
melanocytes are warranted, in view of the potential thera-
peutic targets that may be revealed.
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